Uridine-based gadolinium complex and mri contrast agent including the same
AssigneesKorea Basic Science Institute, Korea University Research and Business Foundation
InventorsJong-Seung Kim, Sankarprasad Bhuniya, Sumin Lee, Kwan Soo Hong, Hyunseung Lee, Hyeyoung Moon
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new uridine nucleoside-based amphiphilic gadolinium complex and a magnetic resonance imaging (MRI) contrast agent including the gadolinium complex. The MRI contrast agent has high relaxivity, high binding affinity for and stability in human serum albumin, pH response, and high liver specificity.
Claims10
A uridine-based gadolinium complex represented by Formula 1:
- wherein each R is H or CH3(CH2)nCO— where n is an integer from 1 to 12.
A ligand represented by Formula 2:
- wherein each R is CH3(CH2)nCO— where n is an integer from 1 to 12.
A method for preparing a uridine-based gadolinium complex of Formula 1, as depicted in Scheme 1-1:
- wherein vi represents GdCl3.6H2O, H2O, and Na2CO3.
A method for preparing a uridine-based gadolinium complex of Formula 1, as depicted in Scheme 1-2:
- wherein v represents TFA and DCM, and vi represents GdCl3.6H2O, H2O, and Na2CO3.
A method for preparing a ligand of Formula 2, as depicted in Scheme 2:
- wherein iv represents RCO2H, EDCI, DMAP, and DMF, and v represents TFA and DCM.
Dependencies are inferred from the claim text.